Omega Launches Aerium With ‘Substantial’ Cash, Two Antibodies Against SARS-CoV-2
Former Takeda Vaccines President Is CEO
Executive Summary
Its antibodies will enter the clinic soon, but pandemic- and epidemic-focused Aerium plans to raise series B funds to take the assets all the way to an EUA in the US and pursue antiviral drug development.